ecancermedicalscience

Research

Prevalence and determinants of lymphedema in newly diagnosed Nigerian breast cancer patients using bioimpedance estimations

9 Feb 2023
Funmilola Wuraola, Olalekan Olasehinde, Matteo Di Bernardo, Patrick Akinyemi, Israel Owoade, Tajudeen Mohammed, Adewale Aderounmu, Samson Ogunleye, Adeoluwa Adeleye, Mary Ogunyemi, Gregory Knapp, Peter Kingham, Olusegun Alatise

Background: Breast cancer-related lymphedema (BCRL) is common and has significant impact on quality of life. Very little is known about BCRL in sub-Saharan Africa. Generally, BCRL has been mostly evaluated post treatment, with very limited data on the prevalence of pre-treatment BCRL at baseline. This study presents the prevalence and clinical associations of lymphedema among newly diagnosed, treatment-naive breast cancer patients in a Nigerian cohort using bioimpedance estimations.

Methods: Consecutively consenting, newly diagnosed, treatment-naive breast cancer patients were assessed for upper limb lymphedema using bioimpedance measurements of the extracellular fluid and the single-frequency bioelectrical impedance analysis value at 5 kHz. Patients were classified as having lymphedema if there was >10% difference in arm measurements or if the ratios of the arm measurements were >3 SD above a normative mean generated from representative controls. Regression analysis was performed to determine clinical variables associated with lymphedema.

Results: There were 154 breast cancer patients with a median age of 47 (40.0–56.8) years and a body mass index of 27 (23.5–30.9) kg/m2. The majority (70%) had stage III disease. All measurements were significantly higher in cases than controls. Using various definitions, the prevalence of lymphedema was between 11.7% and 14.3%. Various clinical variables relating to clinical stage were significantly associated with lymphedema.

Conclusion: The predominance of locally advanced disease in the Nigerian setting is associated with high pre-treatment lymphedema rates. This may set the stage for higher rates in the post-operative setting. Management of lymphedema should be incorporated into the treatment planning.

Related Articles

Nashivai E Kivuyo, Daniel W Kitua, Martin E Chikelea, Mungeni A Misidai, Ally H Mwanga, Obadia V Nyongole, Larry O Akoko
Nithiya Sinarajoo, Yek-Ching Kong, Ranjit Kaur, Ros Suzanna Bustamam, Nur Fadhlina Abdul Satar, Sharminii Jaya-Prakason, Harenthri Devy Alagir Rajah, Mahmoud Danaee, Cheng-Har Yip, Nirmala Bhoo-Pathy